Skip to main content

Advertisement

Log in

Malignancy risk in individuals with familial adenomatous polyposis receiving biologics and immunomodulators

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Clinicians may be hesitant to prescribe biologics or immunomodulators to individuals with familial adenomatous polyposis (FAP) and comorbid inflammatory disease (CID) because of increased cancer risk. Our aim was to compare the risk of malignancy in FAP individuals with inflammatory bowel (IBD) and/or rheumatic disease that received biologics/immunomodulators to those who did not. Individuals with FAP and CID were included in the study. We compared the incidence of cancer between individuals exposed to biologics/immunomodulators compared to unexposed from the date of diagnosis of comorbid disease till last follow up or death. Hazard ratio (HR) for cancer was computed using Cox regression model and compared by exposure status to biologic/immunomodulators. 25 individuals with FAP and a comorbid inflammatory disease were identified including 9 (36%) with IBD and 16 (64%) with rheumatic disease. 14 (56%) were exposed to a biologic and or immunomodulator. Median duration of biologic/immunomodulator exposure was 48 (2–180) months. 3 (21.4%) in the exposed group compared to 1 (9.1%) in the unexposed group developed cancer with a HR for exposure of 1.92 (CI 0.2–18.5, p = 0.57). Median duration of follow up after the diagnosis of inflammatory disease was 10 (5.5–17.0) years in the exposed and 6 (3.0–15.0) years in the unexposed group. In the exposed group, 1 patient developed gastric and 2 developed colon cancer. One unexposed patient developed medullary thyroid cancer. There is a possible trend of more cancers in the group that received biologics/immunomodulators—but given the small number of patients and p-value, there may be no difference at all. This preliminary finding warrants study in a larger cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Burt RW, DiSario JA, Cannon-Albright L (1995) Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 46:371–379

    Article  CAS  Google Scholar 

  2. Wennstrom J, Pierce ER, McKusick VA (1974) Hereditary benign and malignant lesions of the large bowel. Cancer 34(3):850–857

    Article  Google Scholar 

  3. Moisio AL, Jarvinen H, Peltomaki P (2002) Genetic and clinical characterisation of familial adenomatous polyposis: a population based study. Gut 50(6):845–850

    Article  CAS  Google Scholar 

  4. Groen EJ, Roos A, Muntinghe FL, Enting RH, de Vries J, Kleibeuker JH et al (2008) Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 15(9):2439–2450

    Article  Google Scholar 

  5. Knudsen A, Bülow S, Tomlinson I, Möslein G, Heinimann K, Christensen I et al (2010) Attenuated familial adenomatous polyposis: results from an international collaborative study. Colorectal Dis 12(10 Online):e243–e249

    Article  CAS  Google Scholar 

  6. Baugh JA, Bucala R (2001) Mechanisms for modulating TNF alpha in immune and inflammatory disease. Curr Opin Drug Discov Devel 4(5):635–650

    CAS  PubMed  Google Scholar 

  7. Feuerstein J, Nguyen G, Kupfer S, Falck-Ytter Y, Singh S (2017) American gastroenterological association institute clinical guidelines committee. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in inflammatory bowel disease. Gastroenterology 153(3):827–834

    Article  Google Scholar 

  8. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthrit Rheumatol 68(1):1–26

    Article  Google Scholar 

  9. Andrews J, Travis SP, Gibson PR, Gasche C (2009) Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther 29(5):459–469

    Article  CAS  Google Scholar 

  10. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60(11):3180–3189

    Article  CAS  Google Scholar 

  11. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J (2002) Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99(11):3909–3915

    Article  CAS  Google Scholar 

  12. Fukushima K, Funayama Y, Shibata C, Takahashi K, Ogawa H, Kinouchi Y et al (2006) Familial adenomatous polyposis complicated with Crohn’s disease. Int J Colorectal Dis 21(7):730–731

    Article  CAS  Google Scholar 

  13. Gentile N, Kane S (2012) Familial adenomatous polyposis, suspected HNPCC, and Crohn’s disease: two cases. Inflamm Bowel Dis 18(7):1398

    Article  Google Scholar 

  14. Samadder NJ, Gornick M, Everett J, Greenson JK, Gruber SB (2013) Inflammatory bowel disease and familial adenomatous polyposis. J Crohns Colitis 7(3):e103–e107

    Article  Google Scholar 

  15. Fidalgo C, Ferreira S, Rosa I, de Ferro SM, Pereira AD (2013) Familial adenomatous polyposis and Crohn’s disease in one patient: dilemmas and concerns. Case Rep Gastroenterol 7(2):358–362

    Article  Google Scholar 

  16. Urkmez B, Kepekci M, Posul SO, Rezvani A (2017) Coexistence of Peripheral Spondyloarthritis and Familial Adenomatous Polyposis: A Rare Case Report with Treatment Contradictions and Review of the Literature. Ethiop J Health Sci 27(4):441–444

    Article  Google Scholar 

  17. Candeias M, Gaipl S (2016) The immune system in cancer prevention, development and therapy. Anti-Cancer Agents Med Chem (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 16(1):101–107

    Article  CAS  Google Scholar 

  18. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H et al (2002) Critical role for tumor necrosis factor–related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195(2):161–169

    Article  CAS  Google Scholar 

  19. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56(9):2886–2895

    Article  Google Scholar 

  20. Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50(6):1740–1751

    Article  CAS  Google Scholar 

  21. Penn I (1990) Cancers complicating organ transplantation. N Engl J Med 323(25):1767–1769

    Article  CAS  Google Scholar 

  22. Mellemkjaer L, Linet M, Gridley G, Frisch M, Møller H, Olsen J (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32(10):1753–1757

    Article  Google Scholar 

  23. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M et al (2013) Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 145(1):166–75.e8

    Article  Google Scholar 

  24. Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthrit Res Ther 10(2):R45

    Article  Google Scholar 

  25. Lönnfors S, Vermeire S, Avedano L (2014) IBD and health-related quality of life—discovering the true impact. J Crohns Colitis 8(10):1281–1286

    Article  Google Scholar 

  26. Haroon N, Aggarwal A, Lawrence A, Agarwal V, Misra R (2007) Impact of rheumatoid arthritis on quality of life. Mod Rheumatol 17(4):290–295

    Article  Google Scholar 

Download references

Funding

No financial support to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Muhammad Salman Faisal.

Ethics declarations

Conflict of interest

The authors do not have potential conflict of interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Faisal, M.S., Burke, C.A., Achkar, JP. et al. Malignancy risk in individuals with familial adenomatous polyposis receiving biologics and immunomodulators. Familial Cancer 21, 189–195 (2022). https://doi.org/10.1007/s10689-021-00250-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-021-00250-4

Keywords

Navigation